Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Val77 who wrote (11284)	11/14/1998 11:13:00 AM
From: Big Blue	Respond to of 119973

Here is an article referencing GERN, and some of the other BioTechs, this conference might give some momentum to the Biotechs mentioned IMHO FYI... Friday November 13, 5:05 pm Eastern Time Company Press Release Ouch!!! Getting Healthy Without Needles Focus Of Drug Delivery Stocks Forum Nov. 21 In Berkeley BERKELEY, Calif.--(BUSINESS WIRE)--Nov. 13, 1998--One of the biggest hurdles in treating sick patients worldwide is the universal fear of injections -- people hate being stuck by needles. There's hope on the horizon! Whether it's a lollipop-like sucker to treat cancer pain, an inhaler diabetes patients can use to take insulin, or a patch to administer drugs through skin, novel drug delivery techniques and technologies are proliferating. For investors, the companies with drug delivery technologies that win the favor of pharmaceutical manufacturers are poised to prosper and dominate an already enormous and growing industry. Individual investors are invited to see and interact with publicly-traded companies on the cutting edge of the industry at Informed Investors' Drug Delivery Stocks Forum Saturday morning Nov. 21 at the Berkeley Radisson Marina Hotel. In addition to the top executives explaining their science and market opportunities, attendees will get the full picture of the industry and stock ideas from industry analyst Faraz Naqvi of NationsBanc Montgomery Securities. The presenting companies at the Forum are: Aradigm; Endorex; Inhale Therapeutics; Anesta Corp.; Elan plc; DepoMed; Atrix Labs; SuperGen and Matrix Pharmaceutical (Nasdaq:MATX - news). Five of the nine presenting companies are headquartered in the San Francisco Bay Area. ''Every day it seems fascinating developments in bioscience hit the news,'' said Tim Quast, chief operating officer of Informed Investors , Inc., organizer of the Forum. ''Companies like Geron (Nasdaq:GERN - news) and Advanced Cell Technology, for example, are developing processes to grow human cells in the laboratory. ''And earlier this year, EntreMed (Nasdaq:ENMD - news) was the focus of furious stock market trading when a newspaper article cited EntreMed's progress developing two drugs, endostatin and angiostatin, that may hold great potential in battling cancerous tumors,'' Quast continued. ''Certainly, commercial development of new drugs and medical technologies are often years away. Nonetheless, the investment and medical communities find these developments exciting.'' Several of presenting companies at the Forum have been in the news spotlight recently. A week ago, the FDA approved Actiq® from Anesta Corp. (Nasdaq:NSTA - news) to combat chronic pain in cancer victims. Hundreds of thousands of cancer victims suffer ''breakthrough pain,'' sudden, agonizing episodes that break through the regular painkillers taken several times each day. The attacks can last up to two hours. Actiq® has been described in an Associated Press report as ''a raspberry-flavored 'narcotic lollipop' loaded with a painkiller that can seep into the bloodstream faster than any pill.'' Another presenter, Inhale Therapeutics (Nasdaq:INHL - news), said that it and partner Pfizer Inc.(Nyse:PFE - news) are beginning Phase III clinical trials to test the systemic delivery of insulin through the lungs using Inhale's pulmonary delivery system. Phase II results demonstrated that inhaled insulin was as effective as regular injectable insulin. Yesterday, another presenting company, Atrix Labs (Nasdaq:ATRX - news), announced its ATRIDOX antibiotic gel for fast and painless treatment of gum disease is now available nationwide to dental professionals and their patients. The gel provides a ''fast, easy, virtually painless and highly effective treatment'' for periodontal disease, said to be the most common infectious disease after the common cold and the leading cause of adult tooth loss. ''Similar breakthroughs are being announced regularly by the six other presenting companies,'' said Quast. ''For example, Endorex and Elan (NYSE:ELN - news) have an exciting partnership to develop Elan's MediPad(tm), described as a lightweight, painless, disposable drug delivery system which combines the simplicity of a patch with the extensive delivery capabilities of an infusion pump.'' The Forum in Berkeley runs from 8:30 a.m.-1 p.m. The cost is $20 prepaid, $35 at the door. Audio tapes (five-cassette set) are available for $45 plus $3.95 shipping/handling. Call 1-800-992-4683 to register, order tapes or get more information. Visit www.informedinvestors.com for the latest updates. The Forum will also be audio streamed live and archived by Vcall (www.vcall.com). Informed Investors is well established as an important source of current information for medical and biotechnology investors. Since 1993, Informed Investors has featured scores of quality companies and industry experts at its Forums.